Otsuka pens AAV deal with Shape Therapeutics for eye gene therapies
Japanese pharmaceutical company Otsuka has enlisted Seattle-based RNA editing biotech Shape Therapeutics to develop new adeno-associated virus (AAV) vectors. The hope is to find new ways to deliver gene therapies to treat eye diseases.
Shape and Otsuka declined to disclose the upfront payment, but the deal is potentially worth more than $1.5 billion total, including development, regulatory and sales milestones. Shape is also eligible to receive royalties on a gene therapy that uses its AAVs. The new AAVs will be used to develop one-time therapies injected into the whites of the eye, but the partners declined to disclose what diseases or targets the collaboration is for.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.